HF STATS 2026: An Updated Report on Heart Failure Epidemiology and Outcomes from the Heart Failure Society of America

Eiran GorodeskiDirector, Advanced HF & Transplant Center, University Hospitals

“A sobering finding is that despite the availability of highly effect medical therapy, it is underutilized. Only about 18% of patients with HFrEF are on all four pillars of guideline-directed medical therapy. Fewer than 1% reach target doses. Full implementation could save roughly 95,000 lives a year in North America. So the gap is not mainly a gap in knowledge or in drugs. It is a gap in implementation, access and care delivery.”

Dr. Eiran GorodeskiDirector of the Advanced Heart Failure and Transplant Center

“HF is moving in the wrong direction on several fronts at once, even though we have more effective, affordable therapies than ever before. Age-adjusted HF-related mortality has risen about 37% since 2010, which undoes more than a decade of earlier progress, and early 2024 data suggest the rise is continuing.”

Dr. Eiran GorodeskiDirector of the Advanced Heart Failure and Transplant Center

“The landscape of HF in the U.S. has changed, especially among younger adults — aged less than 65 years. HF is no longer just a disease of grandparents. Cardiometabolic HF [with preserved ejection fraction], driven by obesity, hypertension, diabetes and kidney disease has emerged as the predominant new disease in this younger population.”